IGEN is dead, Long live BIOV
IGEN Announces Merger With Roche Completed IGEN Stockholders to Receive Cash and Shares in New Company, BioVeris Corporation; Trading in BioVeris Expected To Begin February 17 on NASDAQ Under Ticker 'BIOV'
--------------------------------------------------------------------------------
Fri Feb 13 16:54:55 2004 EST
GAITHERSBURG, Md., Feb 13, 2004 /PRNewswire-FirstCall via Comtex/ --
IGEN International
Inc. (Nasdaq: IGEN) announced today that it has been acquired by Roche Holding
Ltd and that IGEN will cease trading on The NASDAQ National Market(R) at the
close of business today.
As a result of the transaction, stockholders will receive $47.25 in cash,
without interest, and one share of BioVeris Corporation common stock for each
share of IGEN common stock they owned immediately prior to the closing.
BioVeris common stock has been approved for listing on The NASDAQ National
Market(R) under the symbol "BIOV." Trading in BioVeris is expected to begin
on Tuesday, February 17, 2004. For additional information about BioVeris,
please see the registration statement on Form S-4 filed by BioVeris with the
Securities and Exchange Commission.
On July 24, 2003, IGEN and Roche jointly announced that they had entered
into definitive agreements under which Roche would acquire IGEN and IGEN would
simultaneously distribute the common stock of a new company, BioVeris
Corporation, to its stockholders.
CONTACT: Paul Caminiti or Andrew Cole of Citigate Sard Verbinnen,
+1-212-687-8080
SOURCE IGEN International Inc.
Paul Caminiti or Andrew Cole of Citigate Sard Verbinnen,
+1-212-687-8080
prnewswire.com |
